D8Y0:FRA
SANDOZ GROUP ADR
€71.50
arrow_downward
-0.69%(-0.50) 1D
Sep 8, 8:15:43 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for D8Y0...
Open
€73.50
High
€73.50
Low
€71.50
Mkt. cap
30.00B
Avg. vol.
20.00
Volume
0.00
52-wk high
€79.50
52-wk low
€47.80
No. of employees
20K
Open
€73.50
High
€73.50
Low
€71.50
Mkt. cap
30.00B
Avg. vol.
20.00
Volume
0.00
52-wk high
€79.50
52-wk low
€47.80
No. of employees
20K
News stories
From web sources and news partners
Fierce Pharma
·
19 minutes ago
Sandoz sets sights on 100 biosimilars in new 2040 strategy, with $300M facility build
CNBC
·
5 hours ago
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat
Investing.com Nigeria
·
8 hours ago
Sandoz gains 5% as biosimilars fuel ambitious 2035 growth target By Investing.com
Investing.com
·
11 hours ago
Why is Sandoz stock surging today?
Profile
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars. Wikipedia
About SANDOZ GROUP ADR